Literature DB >> 11033377

Construct validation of the hospital anxiety and depression scale with clinical populations.

M Johnston1, B Pollard, P Hennessey.   

Abstract

OBJECTIVE: the hospital anxiety and depression scale (HADS) attempts to measure anxiety and depression without confounding by somatic symptoms of physical disorder, and is widely used for this purpose. This paper addresses three questions about the validity of the HADS concerning its independence of physical symptoms, the extent to which its items robustly measure the identified constructs with varying clinical populations and situations, and its capacity to differentiate anxiety and depression.
METHODS: data from patients with breast disease, myocardial infarction (MI), and stroke were examined using factor analytic and psychometric analyses.
RESULTS: using exploratory factor analysis in patients with breast disease, 13 of the 14 HADS items fell on a psychological factor and loadings on the psychological factor were higher than loadings on the somatic factor for all items. The HADS showed high levels of internal consistency and there was little evidence that removing items would improve it. Confirmatory factor analyses (CFA) in MI and stroke groups confirmed the separation of anxiety and depression. Analyses indicated items, which were performing poorly for these clinical groups.
CONCLUSIONS: there was support for the validity of the HADS for all three questions. However, there were some evidences of individual items performing poorly. Given the ease of administration and the acceptability of this measure to ill or weak respondents, the HADS continues to perform satisfactorily.

Entities:  

Mesh:

Year:  2000        PMID: 11033377     DOI: 10.1016/s0022-3999(00)00102-1

Source DB:  PubMed          Journal:  J Psychosom Res        ISSN: 0022-3999            Impact factor:   3.006


  71 in total

1.  Treatment effects of partially hydrolyzed guar gum on symptoms and quality of life of patients with irritable bowel syndrome. A multicenter randomized open trial.

Authors:  Giancarlo Parisi; Enrico Bottona; Maurizio Carrara; Fabrizio Cardin; Alessandra Faedo; Dario Goldin; Marco Marino; Maurizio Pantalena; Gianni Tafner; Giorgio Verdianelli; Maurizio Zilli; Gioacchino Leandro
Journal:  Dig Dis Sci       Date:  2005-06       Impact factor: 3.199

2.  Evaluation of uptake and effect on patient-reported outcomes of a clinician and patient co-led chronic musculoskeletal pain self-management programme provided by the UK National Health Service.

Authors:  Joanna K Anderson; Louise M Wallace
Journal:  Br J Pain       Date:  2017-09-26

3.  Testosterone replacement for fatigue in hypogonadal ambulatory males with advanced cancer: a preliminary double-blind placebo-controlled trial.

Authors:  E Del Fabbro; J M Garcia; R Dev; D Hui; J Williams; D Engineer; J L Palmer; L Schover; E Bruera
Journal:  Support Care Cancer       Date:  2013-05-08       Impact factor: 3.603

4.  Evaluation of the Decisional Fatigue Scale Among Surrogate Decision Makers of the Critically Ill.

Authors:  Ronald L Hickman; Grant A Pignatiello; Sadia Tahir
Journal:  West J Nurs Res       Date:  2017-08-14       Impact factor: 1.967

Review 5.  A review and recommendations for optimal outcome measures of anxiety, depression and general distress in studies evaluating psychosocial interventions for English-speaking adults with heterogeneous cancer diagnoses.

Authors:  Tim Luckett; Phyllis N Butow; Madeleine T King; Mayumi Oguchi; Gaynor Heading; Nadine A Hackl; Nicole Rankin; Melanie A Price
Journal:  Support Care Cancer       Date:  2010-07-02       Impact factor: 3.603

6.  Screening for depressive symptoms in patients with unresectable lung cancer.

Authors:  S Néron; J A Correa; E Dajczman; G Kasymjanova; H Kreisman; D Small
Journal:  Support Care Cancer       Date:  2007-02-14       Impact factor: 3.603

7.  Screening for major depressive disorder in adults with cerebral glioma: an initial validation of 3 self-report instruments.

Authors:  Alasdair G Rooney; Shanne McNamara; Mairi Mackinnon; Mary Fraser; Roy Rampling; Alan Carson; Robin Grant
Journal:  Neuro Oncol       Date:  2012-12-09       Impact factor: 12.300

8.  Depression in lung cancer patients: is the HADS an effective screening tool?

Authors:  Lorys Castelli; Luca Binaschi; Paola Caldera; Riccardo Torta
Journal:  Support Care Cancer       Date:  2009-03-13       Impact factor: 3.603

9.  Variables associated with physical health-related quality of life in Parkinson's disease patients presenting for deep brain stimulation.

Authors:  Alexandre Paim Diaz; Fernando Cini Freitas; Maria Emília de Oliveira Thais; Fernando Zanela da Silva Areas; Marcelo Liborio Schwarzbold; Rodrigo Debona; Jean Costa Nunes; Ricardo Guarnieri; Daniel Martinez-Ramirez; Rui Daniel Prediger; Aparna Wagle Shukla; Marcelo Neves Linhares; Roger Walz
Journal:  Neurol Sci       Date:  2016-07-25       Impact factor: 3.307

10.  The role of thalidomide and placebo for the treatment of cancer-related anorexia-cachexia symptoms: results of a double-blind placebo-controlled randomized study.

Authors:  Sriram Yennurajalingam; Jie S Willey; J Lynn Palmer; Julio Allo; Egidio Del Fabbro; Evan N Cohen; Sanda Tin; James M Reuben; Eduardo Bruera
Journal:  J Palliat Med       Date:  2012-08-10       Impact factor: 2.947

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.